These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 2576452)
1. Apparent down-regulation of rat brain mu- and kappa-opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine. Benkelfat C; Aulakh CS; Bykov V; Rice KC; De Costa BR; Rothman RB J Pharm Pharmacol; 1989 Dec; 41(12):865-7. PubMed ID: 2576452 [TBL] [Abstract][Full Text] [Related]
2. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex. Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797 [TBL] [Abstract][Full Text] [Related]
3. Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors. Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW Neuropharmacology; 1990 Sep; 29(9):805-10. PubMed ID: 1963479 [TBL] [Abstract][Full Text] [Related]
4. [3H]cyclofoxy, a ligand suitable for positron emission tomography, labels mu and kappa opioid receptors. McLean S; Rice KC; Lessor R; Rothman RB Neuropeptides; 1987 Oct; 10(3):235-9. PubMed ID: 2825063 [TBL] [Abstract][Full Text] [Related]
5. A brief study of the selectivity of norbinaltorphimine, (-)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitro. Rothman RB; Bykov V; Reid A; De Costa BR; Newman AH; Jacobson AE; Rice KC Neuropeptides; 1988 Oct; 12(3):181-7. PubMed ID: 2853839 [TBL] [Abstract][Full Text] [Related]
6. An examination of the opiate receptor subtypes labeled by [3H]cycloFOXY: an opiate antagonist suitable for positron emission tomography. Rothman RB; McLean S Biol Psychiatry; 1988 Mar; 23(5):435-58. PubMed ID: 2894229 [TBL] [Abstract][Full Text] [Related]
7. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes. Tam SW; Liu-Chen LY J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954 [TBL] [Abstract][Full Text] [Related]
8. Chronic morphine upregulates a mu-opiate binding site labeled by [3H]cycloFOXY: a novel opiate antagonist suitable for positron emission tomography. Rothman RB; McLean S; Bykov V; Lessor RA; Jacobson AE; Rice KC; Holaday JW Eur J Pharmacol; 1987 Oct; 142(1):73-81. PubMed ID: 2826178 [TBL] [Abstract][Full Text] [Related]
9. Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sites. Rothman RB; Bykov V; Long JB; Brady LS; Jacobson AE; Rice KC; Holaday JW Eur J Pharmacol; 1989 Jan; 160(1):71-82. PubMed ID: 2540993 [TBL] [Abstract][Full Text] [Related]
10. Antagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu and delta opioid receptors. Giordano AL; Nock B; Cicero TJ J Pharmacol Exp Ther; 1990 Nov; 255(2):536-40. PubMed ID: 2173747 [TBL] [Abstract][Full Text] [Related]
11. Mu opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain. Titeler M; Lyon RA; Kuhar MJ; Frost JF; Dannals RF; Leonhardt S; Bullock A; Rydelek LT; Price DL; Struble RG Eur J Pharmacol; 1989 Aug; 167(2):221-8. PubMed ID: 2556284 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological and anatomical evidence of selective mu, delta, and kappa opioid receptor binding in rat brain. Mansour A; Lewis ME; Khachaturian H; Akil H; Watson SJ Brain Res; 1986 Dec; 399(1):69-79. PubMed ID: 3026574 [TBL] [Abstract][Full Text] [Related]
13. Characterization of opioid receptors in cultured neurons. Vaysse PJ; Zukin RS; Fields KL; Kessler JA J Neurochem; 1990 Aug; 55(2):624-31. PubMed ID: 2164573 [TBL] [Abstract][Full Text] [Related]
14. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor. Liu-Chen LY; Li SX; Tallarida RJ Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672 [TBL] [Abstract][Full Text] [Related]
15. Solubilization of high-affinity, guanine nucleotide-sensitive mu-opioid receptors from rat brain membranes. Weems HB; Chalecka-Franaszek E; Côté TE J Neurochem; 1996 Mar; 66(3):1042-50. PubMed ID: 8769865 [TBL] [Abstract][Full Text] [Related]
16. The pattern of [3H]cyclofoxy retention in rat brain after in vivo injection corresponds to the in vitro opiate receptor distribution. Ostrowski NL; Burke TR; Rice KC; Pert A; Pert CB Brain Res; 1987 Feb; 402(2):275-86. PubMed ID: 3030494 [TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis of transport and opioid receptor binding of [3H](-)-cyclofoxy in rat brain in vivo: implications for human studies. Sawada Y; Kawai R; McManaway M; Otsuki H; Rice KC; Patlak CS; Blasberg RG J Cereb Blood Flow Metab; 1991 Mar; 11(2):183-203. PubMed ID: 1847702 [TBL] [Abstract][Full Text] [Related]
18. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception. Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046 [TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization and regional quantification of mu, delta and kappa opioid binding sites in rat spinal cord. Stevens CW; Lacey CB; Miller KE; Elde RP; Seybold VS Brain Res; 1991 May; 550(1):77-85. PubMed ID: 1653636 [TBL] [Abstract][Full Text] [Related]
20. Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors. Wang XJ; Han JS J Neurochem; 1990 Oct; 55(4):1379-82. PubMed ID: 2168937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]